Is Egrifta (Tesamorelin) Legal in Virginia?

Federal Legal Status: What FDA Approval Actually Means for Virginia Patients

Tesamorelin holds full FDA approval, which puts it in a different legal category than most peptides discussed in telehealth circles. The FDA first approved Egrifta (tesamorelin 1 mg) in November 2010 for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Theratechnologies then received approval for Egrifta SV (tesamorelin 2 mg) in 2019, consolidating the daily dose into a single injection. [1]

Because tesamorelin is FDA-approved, it is regulated under 21 U.S.C. § 353(b) as a prescription drug. Any licensed physician, nurse practitioner, or physician assistant holding a valid DEA registration and Virginia prescribing authority can write a tesamorelin prescription today.

How Tesamorelin Differs From Unapproved Peptides

Many growth-hormone-releasing peptides, including CJC-1295, ipamorelin, and BPC-157, have never received FDA approval for any indication. They occupy a legal gray area: technically classified as research chemicals or, in some cases, listed on the FDA's bulks list for compounding. Tesamorelin does not share this status. Its FDA-approved new drug application (NDA 022505) gives it a well-defined regulatory identity. [1]

This distinction matters practically. Physicians in Virginia who prescribe unapproved peptides face potential Virginia Board of Medicine scrutiny over standard-of-care questions. Prescribing FDA-approved tesamorelin for its labeled indication carries no comparable regulatory exposure.

Growth Hormone Axis Pharmacology: Why Tesamorelin Works

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It binds GHRH receptors in the anterior pituitary and stimulates pulsatile growth hormone (GH) secretion, which in turn raises insulin-like growth factor 1 (IGF-1). Unlike recombinant human GH, tesamorelin preserves the physiologic feedback loop: when GH rises, somatostatin blunts further secretion, reducing the risk of sustained GH excess. A 2010 NEJM trial (N=412) demonstrated that tesamorelin 2 mg daily reduced visceral adipose tissue (VAT) by 18% versus 2% placebo at 26 weeks (P<0.0001). [2]

Virginia State Law: No Additional Barriers Beyond the Federal Framework

Virginia does not impose restrictions on tesamorelin beyond what federal law already requires. The Commonwealth's Pharmacy Compounding Act (Virginia Code § 54.1-3400 et seq.) tracks federal 503A and 503B frameworks rather than creating independent state hurdles. The Virginia Board of Pharmacy licenses compounding pharmacies and enforces USP <797> sterile compounding standards, but it does not maintain a separate state-level list of prohibited peptides. [3]

The Virginia Board of Medicine (18 VAC 85-20) governs prescribing. Standard-of-care expectations under 18 VAC 85-20-29 require that any prescription, including off-label use, be supported by a bona fide practitioner-patient relationship and appropriate clinical documentation. [4] For on-label tesamorelin prescribing, this threshold is straightforward to meet.

What a "Bona Fide Practitioner-Patient Relationship" Requires in Virginia

Virginia law, aligned with national telemedicine standards, requires the clinician to:

• Collect a complete medical history
• Perform or order appropriate diagnostic testing (fasting IGF-1, fasting glucose, HbA1c, lipid panel)
• Reach an independent clinical judgment
• Maintain ongoing follow-up, not just a one-time consultation

A telehealth visit satisfies this standard in Virginia. The state's telemedicine statutes do not require an in-person visit before prescribing a non-controlled substance like tesamorelin. Virginia enacted HB 2395 in 2020, explicitly permitting prescribing via audio-visual telemedicine without a prior in-person encounter for non-controlled substances. [5]

Documentation Virginia Clinicians Should Maintain

For any tesamorelin prescription, particularly off-label use, Virginia clinicians should document:

• Confirmed HIV-positive status and lipodystrophy diagnosis (for on-label use), or the clinical rationale supporting off-label prescribing
• Baseline fasting blood glucose and HbA1c (tesamorelin raises glucose; the FDA label carries a glucose warning)
• IGF-1 level at baseline and at follow-up
• Informed consent covering the glucose-elevation risk
• Waist circumference or DXA-confirmed VAT measurement where feasible

The FDA-approved Egrifta SV prescribing information specifically warns that tesamorelin may cause glucose intolerance and that patients with diabetes or pre-diabetes require closer monitoring. [6]

The 503A and 503B Compounding Question

This is the most legally nuanced aspect of tesamorelin access in Virginia. Brand Egrifta SV costs roughly $3,000-$4,500 per month without insurance, pushing many patients toward compounded tesamorelin from 503A or 503B pharmacies. Whether compounded tesamorelin is legally dispensed depends on federal compounding law.

503A Pharmacies: Patient-Specific Compounding

Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacies to compound drug products for individual patients with a valid prescription when certain conditions are met. One key restriction: 503A pharmacies may not compound drugs that are essentially copies of commercially available FDA-approved products if the compounded version would be a commercial-scale alternative to the brand drug. The FDA's guidance on essentially-copy restrictions is detailed in its 503A Bulks Guidance documents. [7]

Because Egrifta SV is commercially available, a 503A pharmacy compounding tesamorelin at the same 2 mg daily dose for a patient who has no documented clinical difference from the commercial product could face regulatory challenge. Virginia Board of Pharmacy inspectors follow FDA Memoranda of Understanding (MOU) compliance standards for interstate compounding. A clinician prescribing compounded tesamorelin should document why the patient cannot use the commercial product, such as an inactive ingredient allergy, a documented insurance access failure, or a specific dosing need not met by the commercial formulation.

503B Outsourcing Facilities: The Bulks List Problem

503B outsourcing facilities operate under FDA oversight and may produce compounded drugs in bulk without patient-specific prescriptions, but they may only use bulk drug substances appearing on the FDA's approved 503B Bulks List or the interim 503B Bulks List. As of January 2025, tesamorelin does not appear on the FDA's current 503B Bulks List. [8] This means 503B outsourcing facilities cannot legally compound tesamorelin for bulk distribution.

The practical consequence: if a Virginia patient obtains tesamorelin from a vendor advertising "503B compounded tesamorelin," that vendor is either operating outside FDA rules or mislabeling their regulatory status. Clinicians and patients should verify compounding facility status through the FDA's registered outsourcing facility database.

What Patients Should Verify Before Using a Compounding Pharmacy

• Confirm 503A state licensure with the Virginia Board of Pharmacy (search: dpor.virginia.gov)
• Confirm sterile compounding compliance with USP <797> standards
• Request a Certificate of Analysis (COA) from the pharmacy for each compounded lot
• Ask whether the pharmacy holds PCAB (Pharmacy Compounding Accreditation Board) accreditation, which signals higher quality controls

Clinical Indications: On-Label vs. Off-Label Use in Virginia

FDA approval covers one specific indication: reducing excess visceral abdominal fat in HIV-infected adults with lipodystrophy. Virginia clinicians may prescribe outside this indication under standard off-label prescribing authority, but the evidence base differs substantially between on-label and off-label use.

On-Label: HIV-Associated Lipodystrophy

The Phase 3 LIPO-010 trial and its 26-week extension (combined N=816) established the regulatory evidence base. At 52 weeks, patients on tesamorelin maintained a 17.8% reduction in VAT versus a 4.5% reduction in the placebo-switch group, as reported in the Journal of the Acquired Immune Deficiency Syndromes. [9] Fasting glucose increased by a mean of 3.9 mg/dL in the tesamorelin group versus 0.4 mg/dL in placebo, a statistically significant difference (P<0.001). Virginia clinicians treating HIV-positive patients with documented lipodystrophy can prescribe Egrifta SV on solid FDA-backed evidence.

Off-Label: General Visceral Adiposity and Body Composition

Outside the HIV context, tesamorelin has been studied for visceral adiposity in non-HIV populations, cognitive function, and non-alcoholic fatty liver disease (NAFLD). A 2019 randomized trial published in Diabetes Care (N=61) found that tesamorelin 2 mg daily reduced liver fat fraction by 32% versus 4.5% placebo at 12 months in HIV-negative adults with NAFLD (P=0.005). [10] That data may support off-label use in Virginia patients with NAFLD, though clinicians must weigh the glucose-elevation risk individually.

A 2012 study in JAMA (N=155) found tesamorelin reduced VAT by 15% in non-HIV adults with abdominal obesity over 6 months, compared with no significant change in placebo. [11] Off-label prescribing in Virginia is legal, but insurers will not cover non-HIV indications, and the clinical documentation burden is higher.

Virginia Clinician Decision Framework: Tesamorelin Prescribing Pathway

| Clinical Scenario | Legal Path | Key Documentation | |---|---|---| | HIV+ patient, confirmed lipodystrophy | On-label; brand Egrifta SV preferred | HIV diagnosis, VAT measurement, glucose/HbA1c | | HIV+ patient, insurance denied Egrifta SV | 503A compounding with clinical rationale | Insurance denial letter, ingredient intolerance if applicable | | HIV-negative, NAFLD | Off-label; brand or 503A compound | Liver biopsy or MRI-PDFF, glucose panel, informed consent | | HIV-negative, general adiposity | Off-label; brand or 503A compound | VAT imaging, metabolic labs, detailed informed consent | | Any patient, 503B vendor source | Not legally available via 503B | Do not prescribe via 503B route |

How to Get Egrifta (Tesamorelin) in Virginia: Step-by-Step

Getting a legal tesamorelin prescription in Virginia involves four concrete steps. None of them require unusual effort.

Step 1: Find a Qualified Prescriber

Virginia-licensed physicians (MDs, DOs), nurse practitioners with independent prescribing authority, and physician assistants with a supervising agreement can all prescribe tesamorelin. Endocrinologists, infectious disease specialists, and hormone-therapy-focused internists are the most common prescribers. Telehealth platforms operating in Virginia under HB 2395 are a practical option for patients without easy access to an in-person specialist.

Step 2: Complete Required Lab Work

Before any tesamorelin prescription, a clinician needs:

• Fasting IGF-1 (morning draw, ideally before 10 a.m.)
• Fasting glucose and HbA1c
• Comprehensive metabolic panel
• Lipid panel
• For HIV patients: CD4 count and viral load within the past 6 months

The Endocrine Society's 2019 Clinical Practice Guideline on growth hormone deficiency recommends IGF-1 testing as a standard screening step before any GHRH-axis intervention. [12]

Step 3: Obtain the Prescription

The clinician writes a standard prescription for Egrifta SV 2 mg subcutaneous injection once daily. No special DEA form is required. The prescription can be sent electronically to any licensed pharmacy in Virginia or to a compliant 503A compounding pharmacy if clinical rationale supports compounding.

Step 4: Understand Insurance and Cost

Medicaid in Virginia covers Egrifta SV only for HIV-associated lipodystrophy with prior authorization. Commercial plans vary. Without coverage, the average wholesale price runs $3,000-$4,500 monthly. Theratechnologies operates a patient assistance program (Egrifta4Me) that may reduce costs for eligible patients. Compounded tesamorelin from a 503A pharmacy, when legally appropriate, typically costs $150-$400 monthly, reflecting the substantial difference in manufacturing overhead between a branded biologic and a compounded peptide.

Monitoring During Tesamorelin Therapy in Virginia

The FDA label requires specific monitoring. Virginia clinicians managing tesamorelin therapy should schedule:

• Fasting glucose and HbA1c at 3 months and every 6 months thereafter
• IGF-1 at 3 months (target: upper half of age- and sex-adjusted normal range, not above the upper limit)
• VAT reassessment at 6 months to confirm therapeutic response
• Discontinuation if VAT does not decrease by at least 8% at 6 months, per the LIPO-010 trial responder criteria [9]

The American Association of Clinical Endocrinology (AACE) Position Statement on growth hormone axis therapies notes that IGF-1 levels persistently above the age-adjusted upper limit of normal should prompt dose reduction or discontinuation. [13]

Patients with active malignancy, pituitary tumors, or pregnancy must not use tesamorelin. The prescribing information lists these as absolute contraindications. [6]